High-risk human papillomaviruses (HPVs) are known to be associated with different anogenital cancers including cervical, anal, penile, and vaginal cancers. They are also found to be responsible for the dramatic increases in oropharyngeal squamous cell carcinoma (OPSCC) observed in the United States and Europe. The model for how high-risk HPVs induce cancer formation comes from studies of cervical cancer which usually involves integration of the HPV into the human genome and subsequent changes due to induced chromosomal instability. Recent work, discussed here, however suggests that this model may not be completely correct. In addition, we summarize studies now done in OPSCC which demonstrate that the role of HPV in these cancers may be different from that in cervical cancer. Finally, we propose new models for how HPV may be involved in the formation of these 2 cancers.

Keywords:
Cervical cancer, Common fragile sites, Human papillomavirus, Oropharyngeal squamous cell carcinoma
1.
Adey A, Burton JN, Kitzman JO, Hiatt JB, Lewis AP, et al: The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line. Nature 500:207-211 (2013).
2.
Anorlu RI: What is the significance of the HPV epidemic? Can J Urol 15:3860-3865 (2008).
3.
Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, et al: Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 104:3949-3954 (2007).
4.
Arlt MF, Casper AM, Glover TW: Common fragile sites. Cytogenet Genome Res 100:92-100 (2003).
5.
Badaracco G, Venuti A, Sedati A, Marcante ML: HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. J Med Virol 67:574-582 (2002).
6.
Boldog FL, Gemmill RM, Wilke CM, Glover TW, Nilsson AS, et al: Positional cloning of the hereditary renal carcinoma 3;8 chromosome translocation breakpoint. Proc Natl Acad Sci USA 90:8509-8513 (1993).
7.
Boscolo-Rizzo P, Da Mosto MC, Fuson R, Frayle-Salamanca H, Trevisan R, Del Mistro A: HPV-16 E6 L83V variant in squamous cell carcinomas of the upper aerodigestive tract. J Cancer Res Clin Oncol 135:559-566 (2009).
8.
Callahan G, Denison SR, Phillips LA, Shridhar V, Smith DI: Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene 22:590-601 (2003).
9.
Cha RS, Kleckner N: ATR homolog Mec1 promotes fork progression, thus averting breaks in replication slow zones. Science 297:602-606 (2002).
10.
Chang NS, Pratt N, Heath J, Schultz L, Sleve D, et al: Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 276:3361-3370 (2001).
11.
Chaturvedi AK, Engels EA, Anderson WF, Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26:612-619 (2008).
12.
Connolly DC, Greenspan DL, Wu R, Ren X, Dunn RL, et al: Loss of Fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 6:3505-3510 (2000).
13.
Cowin PA, George J, Fereday S, Loehrer E, Van Loo P, et al: LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res 72:4060-4073 (2012).
14.
Cullen AP, Reid R, Campion M, Lörincz AT: Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 65:606-612 (1991).
15.
Dall KL, Scarpini CG, Roberts I, Winder DM, Stanley MA, et al: Characterization of naturally occurring HPV16 integration sites isolated from cervical keratinocytes under noncompetitive conditions. Cancer Res 68:8249-8259 (2008).
16.
Denison SR, Wang F, Becker NA, Schüle B, Kock N, et al: Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22:8370-8378 (2003).
17.
de Villiers EM: Cross-roads in the classification of papillomaviruses. Virology 445:2-10 (2013).
18.
Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, et al: FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 98:3346-3351 (2001).
19.
Dyson N, Howley PM, Münger K, Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937 (1989).
20.
Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, et al: Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 117:915-919 (2011).
21.
Ferber MJ, Thorland EC, Brink AA, Rapp AK, Phillips LA, et al: Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma. Oncogene 22:7233-7242 (2003).
22.
Franco DL, Nojek IM, Molinero L, Coso OA, Costas MA: Osmotic stress sensitizes naturally resistant cells to TNF-alpha-induced apoptosis. Cell Death Differ 9:1090-1098 (2002).
23.
Gao G, Johnson SH, Kasperbauer JL, Eckloff BW, Tombers NM, et al: Mate pair sequencing of oropharyngeal squamous cell carcinomas reveals that HPV integration occurs much less frequently than in cervical cancer. J Clin Virol 59:195-200 (2014).
24.
Giarnieri E, Zanesi N, Bottoni A, Alderisio M, Lukic A, et al: Oncosuppressor proteins of fragile sites are reduced in cervical cancer. Cancer Lett 289:40-45 (2010).
25.
Glover TW, Berger C, Coyle J, Echo B: DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67:136-142 (1984).
26.
Hidalgo A, Monroy A, Arana RM, Taja L, Vázquez G, Salcedo M: Chromosomal imbalances in four new uterine cervix carcinoma derived cell lines. BMC Cancer 3:8 (2003).
27.
Hosseini SA, Horton S, Saldivar JC, Miuma S, Stampfer MR, et al: Common chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B loss-induced global genome instability. Genes Chromosomes Cancer 52:1017-1029 (2013).
28.
Huang H, Reed CP, Mordi A, Lomberk G, Wang L, et al: Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer 24:48-55 (1999).
29.
Iliopoulos D, Fabbri M, Druck T, Qin HR, Han SY, Huebner K: Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 13:268-274 (2007).
30.
Imai Y, Soda M, Takahashi R: Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275:35661-35664 (2000).
31.
Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, et al: Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 61:1578-1584 (2001).
32.
Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, et al: Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 90:3988-3992 (1993).
33.
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608 (1998).
34.
Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, et al: RB-dependent S-phase response to DNA damage. Mol Cell Biol 20:7751-7763 (2000).
35.
Krummel KA, Roberts LR, Kawakami M, Glover TW, Smith DI: The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics 69:37-46 (2000).
36.
Krummel KA, Denison SR, Calhoun E, Phillips LA, Smith DI: The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1. Genes Chromosomes Cancer 34:154-167 (2002).
37.
Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori K, et al: Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 62:2258-2260 (2002).
38.
Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, et al: The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10:2459-2465 (2004).
39.
Lacey CJ, Lowndes CM, Shah KV: Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 Suppl 3:S3/35-41 (2006).
40.
Lalonde R, Hayzoun K, Selimi F, Mariani J, Strazielle C: Motor coordination in mice with hotfoot, Lurcher, and double mutations of the Grid2 gene encoding the delta-2 excitatory amino acid receptor. Physiol Behav 80:333-339 (2003).
41.
Lee K, Lee MH, Kang YW, Rhee KJ, Kim TU, Kim YS: Parkin induces apoptotic cell death in TNF-α-treated cervical cancer cells. BMB Rep 45:526-531 (2012).
42.
Lemoine FJ, Degtyareva NP, Lobachev K, Petes TD: Chromosomal translocations in yeast induced by low levels of DNA polymerase a model for chromosome fragile sites. Cell 120:587-598 (2005).
43.
Lundberg AS, Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18:753-761 (1998).
44.
Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, et al: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89:857-862 (1997).
45.
Marur S, D'Souza G, Westra WH, Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781-789 (2010).
46.
Matovina M, Sabol I, Grubisić G, Gasperov NM, Grce M: Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. Gynecol Oncol 113:120-127 (2009).
47.
Matsuyama A, Shiraishi T, Trapasso F, Kuroki T, Alder H, et al: Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic. Proc Natl Acad Sci USA 100:14988-14993 (2003).
48.
Mehdi SJ, Alam MS, Batra S, Rizvi MM: Allelic loss of 6q25-27, the PARKIN tumor suppressor gene locus, in cervical carcinoma. Med Oncol 28:1520-1526 (2011).
49.
Minocherhomji S, Ying S, Bjerregaard VA, Bursomanno S, Aleliunaite A, et al: Replication stress activates DNA repair synthesis in mitosis. Nature 528:286-290 (2015).
50.
Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, et al: Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer 136:1494-1503 (2015).
51.
Mishmar D, Mandel-Gutfreund Y, Margalit H, Rahat A, Kerem B: Common fragile sites: G-band characteristics within an R-band. Am J Hum Genet 64:908-910 (1999).
52.
Münger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, et al: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20:7888-7898 (2001).
53.
Murphy SJ, Cheville JC, Zarei S, Johnson SH, Sikkink RA, et al: Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res 19:395-406 (2012).
54.
Nancarrow JK, Holman K, Mangelsdorf M, Hori T, Denton M, et al: Molecular basis of p(CCG)n repeat instability at the FRA16A fragile site locus. Hum Mol Genet 4:367-372 (1995).
55.
Ni S, Hu J, Duan Y, Shi S, Li R, et al: Down expression of LRP1B promotes cell migration via RhoA/Cdc42 pathway and actin cytoskeleton remodeling in renal cell cancer. Cancer Sci 104:817-825 (2013).
56.
Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, et al: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597 (1996).
57.
O'Regan EM, Toner ME, Finn SP, Fan CY, Ring M, et al: p16INK4A genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. Hum Pathol 39:452-458 (2008).
58.
Paige AJ, Taylor KJ, Stewart A, Sgouros JG, Gabra H, et al: A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res 60:1690-1697 (2000).
59.
Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 24 Suppl 3:S3/11-25 (2006).
60.
Pirami L, Giachè V, Becciolini A: Analysis of HPV16, 18, 31, and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. J Clin Pathol 50:600-604 (1997).
61.
Qu J, Lu W, Li B, Lu C, Wan X: WWOX induces apoptosis and inhibits proliferation in cervical cancer and cell lines. Int J Mol Med 31:1139-1147 (2013).
62.
Reshmi SC, Huang X, Schoppy DW, Black RC, Saunders WS, et al: Relationship between FRA11F and 11q13 gene amplification in oral cancer. Genes Chromosomes Cancer 46:143-154 (2007).
63.
Rice DS, Sheldon M, D'Arcangelo G, Nakajima K, Goldowitz D, Curran T: Disabled-1 acts downstream of Reelin in a signaling pathway that controls laminar organization in the mammalian brain. Development 125:3719-3729 (1998).
64.
Rodriguez JA, Barros F, Carracedo A, Mugica-van Herckenrode CM: Low incidence of microsatellite instability in patients with cervical carcinomas. Diagn Mol Pathol 7:276-282 (1998).
65.
Rozier L, El-Achkar E, Apiou F, Debatisse M: Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer. Oncogene 23:6872-6880 (2004).
66.
Saldivar JC, Miuma S, Bene J, Hosseini SA, Shibata H, et al: Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet 8:e1003077 (2012).
67.
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136 (1990).
68.
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505 (1993).
69.
Shen Z: Genomic instability and cancer: an introduction. J Mol Cell Biol 3:1-3 (2011).
70.
Snow K, Tester DJ, Kruckeberg KE, Schaid DJ, Thibodeau SN: Sequence analysis of the fragile X trinucleotide repeat: implications for the origin of the fragile X mutation. Hum Mol Genet 3:1543-1551 (1994).
71.
Song S, Gulliver GA, Lambert PF: Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci USA 95:2290-2295 (1998).
72.
Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, et al: Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58:5032-5037 (1998).
73.
Sutherland GR, Richards RI: The molecular basis of fragile sites in human chromosomes. Curr Opin Genet Dev 5:323-327 (1995).
74.
Takizawa S, Nakagawa S, Nakagawa K, Yasugi T, Fujii T, et al: Abnormal Fhit expression is an independent poor prognostic factor for cervical cancer. Br J Cancer 88:1213-1216 (2003).
75.
Thorland EC, Myers SL, Gostout BS, Smith DI: Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22:1225-1237 (2003).
76.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19 (1999).
77.
Wang YH, Gellibolian R, Shimizu M, Wells RD, Griffith J: Long CCG triplet repeat blocks exclude nucleosomes: a possible mechanism for the nature of fragile sites in chromosomes. J Mol Biol 263:511-516 (1996).
78.
Watson JE, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, et al: Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 23:3487-3494 (2004).
79.
Wei PC, Chang AN, Kao J, Du Z, Meyers RM, et al: Long neural genes harbor recurrent DNA break clusters in neural stem/progenitor cells. Cell 164:644-655 (2016).
80.
White AE, Livanos EM, Tlsty TD: Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 8:666-677 (1994).
81.
Wilson GR, Wang HX, Egan GF, Robinson PJ, Delatycki MB, et al: Deletion of the Parkin co-regulated gene causes defects in ependymal ciliary motility and hydrocephalus in the quakingviable mutant mouse. Hum Mol Genet 19:1593-1602 (2010).
82.
Wu R, Connolly DC, Dunn RL, Cho KR: Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J Natl Cancer Inst 92:338-344 (2000).
83.
Yendamuri S, Kuroki T, Trapasso F, Henry AC, Dumon KR, et al: WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 63:878-881 (2003).
84.
Ying S, Minocherhomji S, Chan KL, Palmai-Pallag T, Chu WK, et al: MUS81 promotes common fragile site expression. Nat Cell Biol 15:1001-1007 (2013).
85.
zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342-350 (2002).
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.